Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
62 studies found for:    prostate cancer, psma, treat
Show Display Options
Rank Status Study
1 Recruiting 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
Conditions: 68Ga-PSMA HBED-PET/CT;   Prostate Cancer
Intervention: Drug: 68Ga- PSMA
2 Recruiting 68Ga-PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Conditions: Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma
Interventions: Device: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC;   Other: Laboratory Biomarker Analysis;   Device: Positron Emission Tomography
3 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
4 Unknown  68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 68Ga-PSMA
5 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
6 Recruiting 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Conditions: Prostate Adenocarcinoma;   PSA Failure;   Recurrent Prostate Carcinoma
Interventions: Procedure: Computed Tomography;   Drug: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
7 Not yet recruiting Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Condition: Prostate Cancer
Intervention: Drug: radium-223 dichloride
8 Recruiting Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy
Condition: Relapsed Prostate Cancer
Intervention: Radiation: External radiation therapy
9 Withdrawn Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Condition: Prostate Cancers
Intervention: Drug: 68Ga-(HBED-CC)-PSMA
10 Active, not recruiting
Has Results
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Interventions: Biological: Peptide Vaccine;   Drug: Poly IC-LC
11 Completed
Has Results
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
12 Recruiting Integrated 18F-labelled PSMA Project
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFPyL
13 Recruiting PET/MRI in Patients With Suspected Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 68Ga- PSMA-HBED-CC;   Device: Biograph mMR, Siemens
14 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
15 Unknown  Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
16 Withdrawn Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Condition: Prostate Cancer
Intervention: Drug: Dendritic cell immunotherapy
17 Recruiting Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F DCFPyL- Radiopharmaceutical
18 Recruiting J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Condition: Prostate Cancer
Intervention: Drug: huJ591
19 Recruiting Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
Condition: Metastatic Castration Resistant Prostate Cancer
Intervention: Drug: Lu177-PSMA-617
20 Not yet recruiting Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Condition: Neoplasm, Prostate
Interventions: Procedure: PET/MR-ultrasound guided Fusion biopsy;   Procedure: Systemic TRUS guided biopsy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.